

Proton Beam Radiation Therapy (PBRT)

Table of Content

[Purpose](#)
[Description & Definitions](#)
[Criteria](#)
[Coding](#)
[Document History](#)
[References](#)
[Special Notes](#)
[Keywords](#)

<u>Effective Date</u>	10/2007
<u>Next Review Date</u>	3/15/2024
<u>Coverage Policy</u>	Medical 101
<u>Version</u>	6

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Purpose:

This policy addresses the medical necessity of Proton Beam Radiation Therapy.

Description & Definitions:

Proton beam radiation therapy (PBRT) is a type of external radiation treatment in which protons are targeted to specific tissue mass by using a stereotactic delivery system. Focused radiation is then delivered to the targeted area.

Criteria:

Proton Beam Radiation Therapy (PBRT) is considered medically necessary for **1 or more** of the following:

- Individual has melanoma of the uveal tract (Ocular melanoma-iris, choroid or ciliary body) and **All** of the following:
 - There is no evidence of metastasis or extrascleral extension
- Individual has chordoma or grade I-II chondrosarcoma of the basisphenoid region (skull base tumor) or cervical spine and **All** of the following:
 - Individual has undergone a biopsy or partial resection of the tumor
 - There is no evidence of metastasis
- Sinonasal cancer and **All** of the following:
 - Tumor involves the base of skull and proton therapy is needed to spare the orbit, optic nerve, optic chiasm, or brainstem
- To treat unresectable, non-metastatic hepatocellular cancer with curative intent
- Individual has arteriovenous malformation with **1 or more** of the following:
 - Intracranial arteriovenous malformation not amenable to surgical excision or other conventional forms of treatment
 - Adjacent to critical structures such as the optic nerve, brain stem or spinal cord
 - Pediatric patients (age less than 21) for **All** of the following:

- Specific cases where adjacent critical structures cannot be adequately spared with Intensity-modulated radiation therapy (IMRT) or stereotactic radiosurgery (SRS)
- Gallbladder cancer, and unresectable intrahepatic tumor
- Head and neck cancer and **ALL** of the following
 - Highly conformal dose distribution required due to close proximity of tissue to critical structures, as indicated by **1 or more** of the following:
 - Cavernous sinus invasion
 - Intracranial invasion
 - Orbital invasion
 - Periocular location
 - Perineural invasion
 - Skull base invasion
 - Radiation oncologist note in medical record documents that other radiation therapy techniques (eg, 3-dimensional conformal radiation therapy, intensity modulated radiation therapy) cannot achieve adequate precision.

Endometrial Ablation is considered **not medically necessary** for uses other than those listed in the clinical criteria, to include but not limited to:

- Breast cancer
- Esophageal cancer
- Gastric cancer
- Gynecologic cancer
- Lung cancer
- Lymphoma (Hodgkin and non-Hodgkin)
- Pancreatic cancer
- Prostate cancer

Coding:

Medically necessary with criteria:

Coding	Description
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex

Considered Not Medically Necessary:

Coding	Description
	None

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2022: April
- 2021: April
- 2019: November
- 2016: March, April
- 2015: March
- 2014: April, October, November
- 2013: March, October
- 2012: March, November
- 2011: January, March, May, July

- 2010: August
- 2009: July
- 2008: July

Reviewed Dates:

- 2023: March
- 2020: April
- 2018: October
- 2017: December
- 2014: March
- 2010: July, December

Effective Date:

- October 2007

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2022, Aug 31). Retrieved Mar 02, 2023, from MCG: <https://careweb.careguidelines.com/ed26/index.html>

(2023). Retrieved Mar 02, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Proton%20beam&keywordType=starts&areald=r3&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance>

(2023). Retrieved Mar 06, 2023, from Department of Medical Assistance Services: <https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=Proton%20beam&gsc.sort=>

ACR–ASTRO Practice Parameter for the performance of Proton Beam Radiation Therapy. (2018). Retrieved Mar 06, 2023, from American College of Radiology: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Proton-Therapy-RO.pdf>

DiBiase, S., & Roach, M. (2022, Oct 19). External beam radiation therapy for localized prostate cancer. Retrieved Mar 02, 2023, from UpToDate: https://www.uptodate.com/contents/external-beam-radiation-therapy-for-localized-prostate-cancer?search=proton%20beam%20§ionRank=1&usage_type=default&anchor=H920638&source=machineLearning&selectedTitle=4~61&display_rank=4#H34

Holt, F., Probert, J., Darby, S., Haviland, J., Coles, C., Kirby, A., . . . Taylor, C. (202, Mar 01). Proton Beam Therapy for Early Breast Cancer: A Systematic Review and Meta-analysis of Clinical Outcomes. Retrieved Mar 06, 2023, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/36868521/>

Koyfman, S. (2022, Oct 10). General principles of radiation therapy for head and neck cancer. Retrieved Mar 02, 2023, from UpToDate: https://www.uptodate.com/contents/general-principles-of-radiation-therapy-for-head-and-neck-cancer?search=proton%20beam%20therapy&source=search_result&selectedTitle=3~61&usage_type=default&display_rank=3

Mitin, T. (2022, Aug 31). Radiation therapy techniques in cancer treatment. Retrieved Mar 02, 2023, from UpToDate: <https://www.uptodate.com/contents/radiation-therapy-techniques-in-cancer->

treatment?sectionName=Proton%20beam&topicRef=7723&anchor=H1070824876&source=see_link#H1070824876

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks. (2023). Retrieved Mar 06, 2023, from National Comprehensive Cancer Network: <https://www.nccn.org/guidelines/guidelines-with-evidence-blocks>

PART 892 -- RADIOLOGY DEVICES. (2023, Jan 17). Retrieved Mar 06, 2023, from Code of Federal Regulations: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=892.5050>

Proton Beam Therapy 2022- 03-13. (2023, Mar 13). Retrieved Mar 02, 2023, from AIM Specialty Health (Carelon Medical Benefits Management): <https://guidelines.carelonmedicalbenefitsmanagement.com/proton-beam-therapy-2022-03-13/>

Proton Beam Therapy for Esophageal Adenocarcinoma. (2022, Oct 21). Retrieved Mar 06, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/hta.pbtsadeno5350>

Proton Beam Therapy for Esophageal Squamous Cell Carcinoma. (2022, Nov 02). Retrieved Mar 06, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/hta.pbtsquamous5351>

Proton Beam Therapy for Prostate Cancer. (2022, Feb 14). Retrieved Mar 06, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/dir.prot0003>

Proton Beam Therapy for Treatment of Breast Cancer. (2022, Oct 14). Retrieved Mar 06, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/hta.pbtbrca5327>

Proton Beam Therapy for Treatment of Chordoma and Chondrosarcoma of the Skull Base. (2023, Feb 15). Retrieved Mar 06, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/dir.pbtchordoma4776>

Proton Beam Therapy for Treatment of Head and Neck Cancer. (2022, Dec 27). Retrieved Mar 06, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/report/dir.protonbeam4736>

Proton Beam Therapy for Treatment of Rhabdomyosarcomas of the Head and Neck Region in Pediatric Patients. (2022, Oct 11). Retrieved Mar 06, 2023, from Hayes, Inc.: <https://evidence.hayesinc.com/report/dir.protonneck3923>

System, Radiation Therapy, Charged-Particle, Medical. (2023, Mar 06). Retrieved Mar 06, 2023, from Food and Drug Administration: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=LHN>

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice,

although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to “correct or ameliorate” (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Keywords:

Proton beam radiation, shp medical 101, PBRT, melanoma, uveal tract, chordoma, chondrosarcoma, basisphenoid region, cervical spine, pituitary adenoma